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Abstract
Background—Perinatally HIV-infected (PHIV) children have, on average, lower bone mineral 
density (BMD) than perinatally HIV-exposed uninfected (PHEU) and healthy children. Low 25-
hydroxy vitamin D [25(OH)D] and elevated parathyroid hormone (PTH) concentrations may lead 
to suboptimal bone accrual.
Methods—PHIV and PHEU children in the Pediatric HIV/AIDS Cohort Study had total body 
(TB) and lumbar spine (LS) BMD and bone mineral content (BMC) measured by dual-energy x-
ray absorptiometry; BMD z-scores (BMDz) were calculated for age-sex. Low 25(OH)D was 
defined as ≤20 ng/mL and high PTH as >65 pg/mL. We fit linear regression models to estimate 
average adjusted differences in BMD/BMC by 25(OH)D and PTH status, and log-binomial models 
to determine adjusted prevalence ratios (aPR) of low 25(OH)D and high PTH in PHIV relative to 
PHEU children.
Results—PHIV children (N=412) were older (13.0 vs.10.8 yr) and more often black (76% vs. 
64%) than PHEU (N=207). Among PHIV, children with low 25(OH)D had lower TB-BMDz 
(−0.38 SD; 95%CI: −0.60 to −0.16) and TB-BMC (−59.1 g; 95%CI: −108.3 to −9.8); high PTH 
accompanied by low 25(OH)D was associated with lower TB-BMDz. Among PHEU, children 
with low 25(OH)D had lower TB-BMDz (−0.34 SD; 95%CI: −0.64 to −0.03). Prevalence of low 
25(OH)D was similar by HIV status (aPR1.00; 95%CI: 0.81 to 1.24). High PTH was 3.17 (95%CI: 
1.25 to 8.06) times more likely in PHIV children.
Conclusion—PHIV and PHEU children with low 25(OH)D may have lower BMD. Vitamin D 
supplementation trials during critical periods of bone accrual are needed.
Keywords
25-hydroxy-vitamin D; parathyroid hormone; HIV infection; children; bone mineral density
Introduction
Adequate attainment of peak bone mass by young adulthood decreases the risk of 
osteoporosis and fragility fractures later in life1 and can be optimized with adequate intakes 
of calcium, phosphorus and vitamin D; sunlight exposure; and regular physical activity.1 
Bone mineralization may be adversely affected by delays in growth and puberty, nutrient 
malabsorption, and chronic infections and inflammation, including human 
immunodeficiency virus infection (HIV). Children with perinatally acquired HIV (PHIV) 
have lower bone mineral density (BMD) compared to healthy children2 and perinatally HIV-
exposed uninfected (PHEU) children.3 There remains a paucity of information regarding 
factors underlying the observed low BMD in PHIV children.
It is likely that low vitamin D status, as reflected by low serum levels of 25-hydroxy vitamin 
D [25(OH)D], and suggested by elevated parathyroid hormone (PTH) levels, contribute to 
Jacobson et al. Page 2
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
suboptimal bone accumulation in PHIV children. Studies in HIV-infected adults report low 
25(OH)D in 13–77% of participants4,5 and associations of low 25(OH)D with bone loss.6 
Among the few studies conducted in HIV-infected children and adolescents, the prevalence 
of low 25(OH)D ranged from 21% to 39% in PHIV adolescents7–11 and ≥50% in 
adolescents behaviorally-infected by HIV.12,13 In PHIV adolescents, lumbar spine BMD was 
lower in those with both low 25(OH)D and high PTH.11 In HIV-infected adults, 25(OH)D 
levels were lower among those initiating antiretroviral therapy (ART) with efavirenz (EFV) 
compared to without EFV14 and baseline PTH levels were higher in HIV-infected 
adolescents receiving ART with tenofovir (TDF) compared to without.12
Few studies have evaluated the relationship of low 25(OH)D and high PTH on bone 
outcomes in large cohorts of PHIV and PHEU children.11 The primary objectives of this 
cross-sectional study were to: a) evaluate associations of low 25(OH)D and high PTH 
concentrations with total body and spine BMD and bone mineral content (BMC); and b) 
assess distributions of 25(OH)D and PTH by HIV status and EFV and TDF exposure.
Methods
The Adolescent Master Protocol (AMP) of the NIH-supported Pediatric HIV/AIDS Cohort 
Study (PHACS) evaluates outcomes of HIV infection and ART among PHIV compared to 
PHEU pre-adolescents and adolescents across 15 clinical sites. The protocol was approved 
by the Institutional Review Boards (IRBs) at each site and the Harvard T.H. Chan School of 
Public Health. Informed consent from the parent(s) or guardian(s), and assent from 
participants were obtained per local IRB guidelines.
Data Collection
Socio-demographic and clinical history—Clinical and laboratory data, including 
sociodemographics and Tanner staging, were obtained as previously described.15 Tanner 
stage was ascertained by inspection of breasts and pubic hair for females and of genitalia 
and pubic hair for males at semi-annual visits until Tanner stage 5 was reached. For boys and 
girls, the more advanced stage of the two respective pubertal components was used for 
classification if there was discordance between the examined body sites (e.g., breast vs. 
pubic hair in females). Weight, height and BMI were expressed as z-scores.16 Season at the 
time of blood draw was categorized as winter, spring, summer, or fall based on solstice 
dates. Latitude was considered both as a categorical [sites classified as northern (≥39°) or 
southern (< 39°)] and a continuous variable.
Continental ancestry—Since circulating levels of both 25(OH)D and BMD vary by race, 
we included genetic ancestry informative markers to adjust for residual confounding in 
addition to self-reported race and ethnicity. A panel of 41 single nucleotide polymorphisms 
(SNP) ancestry informative markers was used to determine continental ancestry which was 
estimated by comparing each child’s genotype to allele frequencies in a reference set of 
3517 individuals.17 Reference populations were originally grouped into the seven world-
regions: Europe, Africa, America, Central/South Asia, South/West Asia, East Asia, and 
Oceania. We determined the percentage of each region present within an individual which 
totals 100%.18,19 Due to the small number of Asians in the study, we combined Europe, 
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Central/South Asia, and South/West Asia (Europe/CSW Asia) by adding the regional 
ancestry percentage.
Bone outcomes—Total body (TB)-BMD including head, and lumbar spine BMD (LS-
BMD), TB bone mineral content including head (TB-BMC) and less head (TBLH-BMC), 
lumbar spine BMC (LS-BMC), percent body fat (%), and extremity lean mass (g) were 
measured on a Lunar or Hologic dual energy x-ray absorptiometry (DXA) scanner (General 
Electric Healthcare, UK or Hologic Inc., Bedford, MA) as previously described.3 A phantom 
was circulated to each clinical site to standardize results. Scans were sent to the Body 
Composition Analysis Center at Tufts University School of Medicine for central analysis 
and standardization. Hologic scans were analyzed using Hologic QDR version 12.3 and 
APEX version 3.3. Lunar scans were analyzed using Prodigy Advance enCORE 2005 
version 9 and enCORE 2011 version 13.6. All scans were analyzed by a single technician 
blinded to the participants’ HIV status. Bone age was assessed using x-rays of the left hand 
and wrist by a radiologist at each clinical site blinded to HIV status, and TB and LSBMD z-
scores for age and sex (BMDz) were calculated using normative BMD data.3,20 For children 
between Tanner stages 1–4 with a chronologic age (CA) that differed by more than 1 SD 
from the bone age (BA), the BA was used instead of the CA in the TB-BMD and LS-BMD 
calculations.3 For children at Tanner stage 5, CA was used. Children between Tanner 
stages1–4 were excluded from analyses of BMDz if their bone age was missing.
Laboratory measures—For this cross-sectional analysis, we selected a repository blood 
specimen (see Table, Supplemental Digital Content 5) drawn within 1 year of a DXA scan 
(generally the first DXA scan). If no specimen was available within 1 year of the DXA or no 
DXA was completed, we selected the earliest available repository specimen. Measurements 
of laboratory variables were performed in batch at the USDA-ARS WHNRC, (Davis, 
California).25(OH)D was measured by enzyme-linked immunosorbent assay (ELISA, 
Immunodiagnostic System, (ids) Inc. Gaithersburg, MD). Serum intact PTH was measured 
using a solid phase, two-site chemiluminescent enzyme-labeled immunometric assay (Intact-
PTH, Siemens Medical Solutions Diagnostics, Tarrytown, NY). Calcium, phosphate, and 
creatinine were determined using a clinical chemistry analyzer (Cobas Integra 400 Plus 
[04469658]: Roche Diagnostics Corp., Indianapolis, IN). Samples were assayed in duplicate 
and the mean of each pair was calculated. Low 25(OH)D status was defined as ≤20.0 ng/mL 
and deficient 25(OH)D as <12 ng/mL.21 High PTH was defined as >65pg/mL. (http://
labmed.ucsf.edu/labmanual/db/resource/Immulite_2000_Intact_PTH.pdf.)
Database records from children with high PTH and /or high phosphate levels (>5.4 mg/dL) 
were reviewed for evidence of concurrent clinical diseases (pancreatitis, chronic kidney 
disease, inflammatory bowel disease, neonatal renal failure, and nephrolithiasis).
Dietary recall and physical activity—The Block Dietary Questionnaire and Physical 
Activity Screener for Children and Adolescents were administered to assess dietary intake 
including supplement use and physical activity, respectively, over the past week (Block 
Dietary Data Systems, Nutriquest, Berkeley, CA). The recommended daily dietary 
allowance (RDA) for calcium was ≥1100 mg for ages 4–8 years and ≥1300 mg for ages 9–
18 years, and vitamin D was ≥600 IU/day for ages 1–18 years of age.22 Minutes of vigorous 
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physical activity were categorized into >75th percentile (> 25.2 minutes/day) or ≤75th 
percentile (≤25.2 minutes/day) based on our data distribution.
Statistical Methods—The distribution of socioeconomic and clinical covariates by HIV, 
25(OH)D, and PTH status was compared using Wilcoxon test/Kruskal Wallis for continuous 
and Chi-square for categorical variables. A variable was constructed for combinations of low 
25(OH)D and high PTH.
Linear regression models were fit with the robust variance to evaluate differences in bone 
outcomes by 25(OH)D and PTH status in PHEU and PHIV separately. Effect modification 
of 25(OH)D by HIV status was tested in models that included both PHIV and PHEU 
children. Potential confounders were chosen a priori based on literature review and expert 
knowledge. Adjusted models of bone outcomes included age at vitamin D measure, black 
race, continental ancestry (African, Europe/CSW Asia, and other), height z-score, extremity 
lean mass, and vigorous activity >75th percentile. We additionally adjusted for percent body 
fat when 25(OH)D status was the exposure and for Tanner stage and sex when the outcome 
was TB-BMC, TBLH-BMC, or LS-BMC. We did not include season and latitude as 
potential confounders because we did not hypothesize an effect on bone other than through 
25(OH)D. Missing indicators were included for those missing information about race and 
vigorous activity.
Log-binomial regression models were fit to obtain the unadjusted (uPR) and adjusted 
prevalence ratio (aPR) of low 25(OH)D and high PTH in PHIV compared to PHEU, and for 
current TDF and EFV use compared to PHEU children. When the log-binomial model did 
not converge, a Poisson model was fit.23 To estimate average differences in 25(OH)D and 
PTH levels by the above groups, we fit linear regression models with a robust variance 
estimator. All models were adjusted for black race and continental origin. 25(OH)D models 
were additionally adjusted for season and latitude. PTH levels may be higher in TDF users 
possibly due to phosphate wasting. Thus, as a secondary aim, we fit linear regression models 
to determine the relationship of PTH with calcium levels by HIV and TDF status. PHIV 
children without ARV information or not using ARVs at the 25(OH)D assessment were 
excluded from analyses of EFV or TDF. Analyses were performed in SAS 9.4 (SAS 
Institute, Cary, NC).
Results
Characteristics
Of the 448 PHIV and 226 PHEU children with an entry visit in AMP, 25(OH)D was 
measured in 426 and 219, respectively. Continental ancestry was available as well as 
25(OH)D on 412 PHIV and 207 PHEU. In the final dataset, 394 of 412 PHIV and 199 of 
207 PHEU had a DXA scan within one year of the 25(OH)D measure, with a median 
(interquartile range, IQR) of 0 days (1, 39).
The distribution and unadjusted comparison of socioeconomics, lifestyle characteristics, 
anthropometrics, and laboratory values between PHIV and PHEU children are shown in 
Table 1. The prevalence of low 25(OH)D was 40% overall and higher in PHIV compared to 
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PHEU (42% vs. 34%). Average PTH concentrations were higher in PHIV and 9% of PHIV 
and 2% of PHEU had high PTH. Among PHIV with high PTH and without low 25(OH)D, 
the range of 25(OH)D levels was 21.1to 25.5 ng/mL in 10children, 29.4 to 32.6 in 4children, 
and was52.4 ng/mL in one child.
Diagnoses among children with high PTH and/or phosphate levels
Among the 50 children with high PTH and/or high phosphate, only one child had a relevant 
clinical diagnosis other than HIV, i.e., chronic kidney disease. That child was included in all 
analyses. None of the PHEU children had a relevant diagnosis.
Association of 25(OH)D and PTH with bone
Among PHIV children (Table 2), those with low 25(OH)D compared to those without had 
adjusted TB-BMD z-scores that were on average 0.38 SD lower (95% confidence interval 
(95%CI): −0.60 to −0.16) and TB-BMC levels that were59.1 g lower (95%CI: −108.3 to 
−9.8). In an unadjusted analysis, this represents a 5.9% lower TB-BMC. Similar results were 
observed for TBLH-BMC. Among PHEU children, adjusted TB-BMD z-scores were on 
average 0.34 SD lower (95%CI−0.64, −0.03)in children with low 25(OH)D, but there were 
no differences for TB-BMC and TBLH-BMC. In models including PHIV and PHEU 
children, there was no strong indication of effect modification of HIV status by low 25(OH) 
for any of the bone outcomes (P>0.29), but power may be limited.
The average adjusted difference in LS-BMD z-scores between those with versus without low 
25(OH)D was −0.21 SD (95%CI −0.42, 0.0) for PHIV and 0.10 SD (95%CI −0.30, 0.51) for 
PHEU. There were no differences in LS-BMC by 25(OH)D status in PHIV or PHEU 
children.
There was no apparent difference in any bone outcome by PTH status among PHIV children 
(Table 2). The average difference in TB-BMD z-scores was −0.02 (95%CI: −0.37, 0.42) 
between those with high versus normal PTH. However, TB-BMD z-scores were on average 
0.48 SD lower (95%CI: −0.92 to −0.03) in children with low 25(OH)D and high PTH and 
0.28 SD units lower (95%CI: −0.51 to−0.05) in those with low 25(OH)D and normal PTH, 
compared to the reference group (25(OH)D >20 ng/mL and PTH ≤65 pg/mL) (See Table, 
Supplemental Digital Content 1). LS-BMC was on average 3.1 g lower (95%CI: −6.2 to 
0.05) in PHIV with low 25(OH)D and high PTH compared to the reference.
Differences in characteristics by 25(OH)D and PTH status in PHIV and PHEU children
Characteristics associated with low 25(OH)D for PHIV and PHEU children combined 
included older age, female sex, black race, African ancestry, blood drawn in winter or 
spring, northern latitude, Tanner stage >1, higher percent body fat, lower calcium and 
phosphate, and higher PTH and creatinine (Table 3) (See Table, Supplemental Digital 
Content 2). Among the PHIV, children with low 25(OH)D had lower CD4 counts and were 
more likely to receive EFV.
Factors associated with high PTH were older age, African ancestry, Tanner stage >1, lower 
25(OH)D and calcium, and higher creatinine. Among PHIV children, those with high PTH 
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had a lower frequency of EFV use, a higher frequency of TDF use, and higher HIV viral 
load. (Supplemental Digital Content 3). (48 of 401 received both TDF and EFV).
Prevalence of low 25(OH)D in PHIV compared to PHEU children
The adjusted prevalence ratio (95%CI) of low 25(OH)D was 1.00 (0.81 to 1.24) in PHIV 
relative to PHEU (Table 4, Model 1B), 1.30 (0.98 to 1.74) in PHIV receiving EFV compared 
to PHEU (Model 2B), and 0.95 (0.76 to 1.18) in PHIV not receiving EFV compared to 
PHEU children (Table 4, Model 2B). The opposite trend was observed for PHIV receiving 
TDF compared to PHEU (aPR= 0.77 (0.56 to 1.06, Model 3B). Differences in mean 
25(OH)D levels by HIV, and by EFV and TDF use, suggest similar results (Table 4, Models 
7B–9B).
Prevalence of high PTH in PHIV compared to PHEU children
PHIV had a 3.17 (1.25 to 8.06) times greater adjusted prevalence of high PTH than PHEU 
children (Table 4 Model 4B). The average difference between groups was 5.26pg/mL (−2.35 
to 8.17). PHIV who were not receiving EFV (Table 4, Model 5B) had a 3.67 times higher 
prevalence of high PTH than PHEU (1.44 to 9.36). The prevalence of high PTH (Table 4, 
Model 6B) was 5.50 (1.95 to 15.49) times higher in PHIV receiving TDF compared to 
PHEU, and 2.64 times higher in PHIV not receiving TDF (1.01 to 6.94) than in PHEU 
children. Compared to PHEU, PTH concentrations were on average 5.54 pg/mL higher in 
PHIV not receiving EFV (Table 4, Model 11B) and 11.65 pg/mL higher in those receiving 
TDF (Table 4, Model 12B), compared to PHEU.
Relationship between calcium and PTH by HIV status and TDF use
Serum calcium and PTH were negatively associated in PHIV not receiving TDF (slope 
−10.5, P=0.001) and PHEU (slope −7.6, P=0.002) but not associated among PHIV receiving 
TDF (slope −3.8, P=0.56) (See Figure, Supplemental Digital Content 4).
Discussion
In this multi-center cohort of PHIV and PHEU children in the US, 40% had vitamin D 
deficiency overall and the prevalence did not differ by HIV status after careful adjustment 
for confounding. In both PHIV and PHEU children, low 25(OH)D was associated with 
lower TB-BMD, but not with LS-BMD in either cohort. PTH levels were highest in PHIV 
children receiving TDF. While PTH levels were, on average, higher in PHIV children with 
low 25(OH)D, high PTH was only associated with lower TB-BMD when accompanied by 
low 25(OH)D. The relationship between calcium and PTH was weak in PHIV children 
receiving TDF.
Several randomized clinical trials (RCTs) have been done examining effects of vitamin D 
supplementation in healthy children and adolescents.24 A meta-analysis of six such RCTs 
found that children with normal baseline 25(OH)D concentrations (>18 ng/mL) did not have 
benefits in BMD accrual from supplementation, but that there was a significant positive 
effect of supplementation on total body and a borderline significant effect on spine BMD 
among those with low levels of 25(OH)D at baseline.25 Four cross-sectional studies in 
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normal children of the relationship of 25(OH)D as a continuous variable with BMD all 
found positive associations with whole body BMD26–29, two with lumbar spine26,29, one 
with total hip29, and one with the forearm.28 No associations were found in five other cross-
sectional studies.30–34 We previously found that TB-BMD was greater in PHIV children 
using vitamin supplements.35 In a study of vitamin D and calcium supplementation over 2 
years in PHIV children, 25(OH)D levels increased, but this did not significantly increase 
total body or spine BMC or BMD measures over time.7 In the aforementioned study, those 
who advanced through puberty during the study period had a greater increase in TB-BMC 
and LS-BMC in the supplemented group, but this result did not achieve significance. Thus, 
our finding that low 25(OH)D was associated with decreased total body BMD and BMC is 
supported by some, but not all studies. Since the effect sizes on BMD from vitamin D 
supplementation appear to be modest, and many prior studies have used low doses of 
vitamin D supplementation (as little as 133 IU/day) and included children who at baseline 
were vitamin D-replete, further adequately powered studies examining effects of vitamin D 
supplementation to target adequate 25(OH)D serum concentrations across puberty, 
particularly in children with PHIV with baseline vitamin D deficiency or insufficiency, are 
needed.
It is unclear why we found no associations with LS-BMD/BMC in either group or with TB-
BMC in PHEU children. In contrast to these studies, we evaluated the effect of categorically 
low 25(OH)D compared to 25(OH)D as a continuous variable. This is based on clinical 
evidence that the relationship between 25(OH)D and BMD may not be linear and that those 
at the lowest levels of 25(OH)D may benefit most from supplementation.21 The lack of 
association between high PTH and bone outcomes in our study is possibly a result of 
competing reasons for higher PTH values, including low 25(OH)D, additional requirements 
for calcium and phosphate during rapid bone accrual, and effects of TDF on PTH.12 This is 
supported by our finding of lower TB-BMD when high PTH was accompanied by low 
25(OH)D.
Vitamin D deficiency is common in the US.36–38 The 40% prevalence of low 25(OH)D in 
our cohort was similar to those of cohorts of healthy children in the northeastern US37 and 
PHIV children in New York City.7 Our prevalence of vitamin D deficiency was higher than 
the 24% observed in 6–18 year-old children in the NHANES representative US sample of 
this age group,38 but lower than the ≥50% reported in behaviorally HIV-infected 
adolescents.12,13 Differences across studies are likely attributable to age, race, prevalence of 
obesity, latitude, sun exposure, season of sampling, and dietary intake.
While low 25(OH)D was equally prevalent in our PHIV and PHEU children overall after 
adjustment for known confounders37,39 low 25(OH)D concentrations may be more common 
in PHIV receiving EFV than in PHEU, although our power to detect a significant difference 
between groups may be too low. This is consistent with adult studies,14 and may be 
explained by in vitro evidence of EFV induction of the P450 enzyme CYP24,40 which 
converts 25(OH)D to its inactive form, calcitroic acid. PHIV children had higher vitamin D 
intake than did PHEU, but HIV providers may check 25(OH)D levels in their PHIV patients 
and recommend supplementation.
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Calcium is important to optimize bones and tooth mineralization, and for catalytic and 
mechanical functions throughout the body. The body tightly regulates ionized calcium 
levels. When the calcium supply is insufficient, PTH concentrations increase. PTH increases 
serum calcium through a variety of mechanisms. PTH mobilizes calcium adsorbed to the 
bone surface by breaking down bone mineral and matrix and it stimulates conversion of 
25(OH)D to 1,25-dihydroxyvitamin D (1,25(OH)(2)D) which increases gut calcium 
absorption and renal calcium reabsorption. During the rapid linear growth and bone accrual 
of puberty, there is increased demand for calcium and phosphate, and PTH levels 
increase.4142 PTH measurements also provide an assessment of the level of “stress” on the 
system as a result of low 25(OH)D concentrations, although the degree of serum PTH 
suppression may not determine optimal vitamin D status in children.43
TDF use has been previously associated with increases in serum concentrations of PTH,12,44 
with multiple mechanisms implicated. TDF appears to have effects on both bone and 
hormones [such as fibroblast growth factor-23 and 1,25(OH)2D] that may indirectly increase 
PTH.45–47 TDF use can also result in renal tubular dysfunction stimulating production of 
PTH and in renal phosphate-wasting44 which may, in part, be PTH-mediated.12 In HIV-
infected adolescents, baseline PTH levels were higher in TDF users regardless of 25(OH)D 
status. With vitamin D supplementation, PTH levels decreased in the TDF group, but did not 
change in those not receiving TDF.12 In our cohort, PTH levels were higher in those with 
low 25(OH)D; highest at Tanner stages 3–4, the time of most rapid bone accrual; and higher 
among TDF users. PTH concentrations were not strongly associated with serum calcium 
among TDF users, suggesting other mechanisms for elevated PTH.
Our study has several limitations. While 25(OH)D is a stable vitamin D metabolite with a 
biological half-life of 2–3 weeks, levels vary by season; thus, one measurement may not 
represent the average yearly level.48 However, children with 25(OH)D deficiency at one time 
of the year tend to be deficient at other times during the year49 which favors using the ≤20 
ng/mL cut-off recommended by the Global Consensus Recommendations on Prevention and 
Management of Nutritional Rickets.21 While imperfect, we adjusted for season when 
evaluating prevalence or differences in 25(OH)D by subgroups. We recognize that the 20 
ng/mL cutoff is based upon what is needed to prevent rickets and osteomalacia,21 but 
concentrations required for optimal bone and immunological health are likely higher.50 
Using this lower threshold, we could examine characteristics of those most likely to have 
clinically significant deficiency. Since this was a cross-sectional study where 25(OH)D, 
PTH, and DXA parameters were measured within one year of each other, we could not 
establish a temporal relationship between low 25(OH)D or high PTH, and subsequent bone 
accrual. While this is an important limitation, BMD ranking tracks well over time in healthy 
children such that those who ranked among the lowest earlier in childhood also ranked 
among the lowest later in adolescence, and those who ranked highest generally remained 
high.51 When evaluating prevalence of high PTH, confidence intervals were wide due to few 
children having high PTH. Finally, our findings might not be generalizable to populations 
other than the US where there is a difference in the distribution of continental ancestry and 
nutritional status.
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Children gain more than half of their peak bone mass during adolescence with the greatest 
increase following the pubertal growth spurt, highlighting the need to identify modifiable 
factors during this critical period that could improve bone accrual. This study afforded a 
unique opportunity to further quantify risk factors for poor bone health, specifically low 
25(OH)D. This may lead to novel vitamin D supplementation trials that could ameliorate 
deficits and improve bone health at critical developmental stages.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1
Sociodemographic, Clinical and Laboratory Characteristics at the Time of Blood Draw by HIV Status
Cohort
Characteristic1
PHIV
(N=412)
PHEU
(N=207)
P
Value
Median (Q1, Q3) or N(%)
Age (yr) 13.0 (10.6, 14.7) 10.8 (9.0, 12.8) < 0.001
Sex-male 195 (47%) 106 (51%) 0.36
Hispanic (self-reported) 100 (24%) 70 (34%) 0.01
Black race (self-reported) 298 (76%) 129 (64%) 0.002
Continental ancestry (%)2
  Africa 69.8 (23.5, 81.4) 62.0 (8.7, 77.1) 0.01
  Europe/CSK Asia 17.5 (6.69, 50.4) 23.5 (9.5, 58.4) 0.02
  Americas 1.9 (1.3, 3.8) 2.1 (1.4, 4.7) 0.06
  East Asia 3.1 (2.1, 4.9) 3.4 (2.1, 5.2) 0.15
  Oceania 3.4 (2.0, 5.9) 3.4 (2.1, 6.2) 0.57
Season of blood draw Spring 110 (27%) 54 (26%) < 0.001
Summer 124 (30%) 58 (28%)
Fall 95 (23%) 26 (13%)
Winter 83 (20%) 69 (33%)
Northern latitude3 Northern 250 (61%) 103 (50%) 0.01
Vigorous activity (min/day) 8.4 (0.0, 30.0) 9.6 (0.0, 34.2) 0.09
Vitamin D intake (IU/day) 160 (93, 320) 135 (79, 248) 0.03
Vitamin D intake < 600 IU/day 363 (94%) 193 (97%) 0.12
Calcium intake (mg/day) 713 (480, 1,029) 700 (480, 1,004) 0.65
Calcium intake < 1300 mg/day4 326 (84%) 173 (87%) 0.42
Phosphorus intake (mg/day) 1,016 (726, 1,452) 9670 (701, 1,387) 0.37
Weight z-score 0.15 (−0.76, 1.01) 0.84 (−0.20, 1.83) < 0.001
Height z-score −0.30 (−1.13, 0.38) 0.27 (−0.43, 0.97) < 0.001
Percentage body fat (%)5 22.3 (15.1, 30.4) 26.1 (18.6, 36.9) < 0.001
Tanner stage6 1 86 (21%) 65 (32%) < 0.001
2 77 (19%) 58 (28%)
3 77 (19%) 28 (14%)
4 79 (19%) 32 (16%)
5 91 (22%) 22 (11%)
Laboratory
25(OH)D (ng/mL) 22.0 (16.3, 27.7) 22.6 (18.4, 27.0) 0.17
25(OH)D ≤ 20 ng/ml 175 (42%) 71 (34%) 0.05
25(OH)D (ng/ml) < 12.0 34 (8%) 10 (5%) 0.11
12.1–20.0 141 (34%) 61 (29%)
>20.0 to 29.9 161 (39%) 100 (48%)
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Cohort
Characteristic1
PHIV
(N=412)
PHEU
(N=207)
P
Value
≥30 76 (18%) 36 (17%)
PTH (pg/mL) 31.1 (22.3, 45.9) 26.2 (20.1, 37.4) < 0.001
PTH >65 pg/ml > 65 pg/mL 38 (9%) 5 (2%) 0.002
25(OH)D and PTH 25D ≤20 PTH >65 23 (6%) 2 (1%) 0.006
25D ≤20 PTH ≤65 152 (37%) 69 (33%)
25D>20 PTH >65 15 (4%) 3 (1%)
25D >20 PTH ≤65 222 (54%) 132 (64%)
Calcium (mg/dl) 9.6 (9.3, 9.9) 9.7 (9.5, 10.0) < 0.001
Phosphorus (mg/dL) 4.5 (4.1, 5.0) 4.9 (4.5, 5.2) < 0.001
Creatinine (mg/dL) 0.56 (0.47, 0.65) 0.54 (0.48, 0.62) 0.14
Among PHIV
Type of ART regimen
PI 40 (9.7)
NNRTI 65 (15.8)
PI 263 (63.8)
Other ART 40 (9.7)
No ART 4 (0.10)
Lifetime duration of ARV 10.7 (8.6, 12.7)
Efavirenz – current use7 73 (18%)
  Lifetime duration (yr) 3.1 (1.5, 6.1)
Tenofovir – current use7 91 (23%)
  Lifetime duration (yr) 1.5 (0.5, 2.8)
CD4 T cell count (cells/mm3) 699 (508, 919)
CD4 percent before ART initiation (%) 30.0 (21.0, 38.0)
HIV RNA (log10 copies/mL) 2.2 (1.7, 3.1)
HIV RNA < 400 copies/mL 277 (67%)
Abbreviations: PHIV-perinatally HIV-infected; PHEU-perinatally HIV-exposed uninfected; 25(OH)D -25 hydroxy-vitamin D; ART-antiretroviral.
1
Missing data for PHIV and PHEU : Hispanic (N=1, N=3); Black race (N=21, N=6); Birthplace (N=2.N=0); vigorous activity (N=79, N=14);); 
dietary intake (N=26, N=8); Tanner stage (N=2, N=2); PTH (N=0, N= 1); calcium (N=5, N=0), phosphate/creatinine (N=1, N=0); CD4 count 
(N=2); HIV viral load (N=0).
2Continental origin (%) - The percent for each region is the percent present within an individual for that region. When looking by HIV status, it is 
the median of those individual percents for that region.
3Northern: ≥ 39° degree latitude.
4
The RDA for calcium is 1100 for children 4–8 years old and 1,300 for children 9–18 years old.
5No percent body fat measured on N=21 PHIV, N=8 PHEU) because there was no DXA scan within 365 days of the 25(OH)D.
6
If Tanner stage was missing at the time of 25(OH)D assessment, we carried forward the Tanner stage assessment from the previous annual or 
semi-annual visit, except for 4 children on which there was no previous Tanner stage assessment in AMP.
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7
Twelve PHIV children are not included in these numbers. For 8 children the last information on ARV use was just prior to the 25(OH)D date, for 2 
children ARV was started for the first time after the 25(OH)D date, and for2 children ARVs were never used. Of the 8 children with previous ARV 
use just prior to the 25(OH)D date, 1 had been on TDF, 2 on EFV, 1 on TDF and EFV, and 4 on neither TDF or EFV.
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Table 3
Differences in Sociodemographic, Clinical and Laboratory Characteristics by 25(OH)D Status at Time of 
Blood Draw - PHIV and PHEU Children Combined
25(OH)D Level
Characteristic1
≤ 20 ng/mL
(N=246)
> 20 ng/mL
(N=373)
P
Value
Median (Q1, Q3) or N(%)
Age (yr) at 25(OH)D assessment 13.1 (10.7, 14.8) 11.9 (9.3, 13.8) < 0.001
Sex-M 98 (40%) 203 (54%) < 0.001
Black race 198 (83%) 229 (65%) < 0.001
Continental ancestry (%)
  Africa 72.0 (52.4, 81.9) 55.5 (8.0, 78.4) < 0.001
  Europe/CSK Asia 13.9 (6.3, 30.8) 27.2 (9.0, 62.9) < 0.001
  Americas 1.9 (1.3, 3.4) 2.1 (1.3, 4.7) 0.09
  East Asia 3.1 (2.1, 4.7) 3.2 (2.1, 5.1) 0.52
  Oceania 3.3 (2.2, 5.6) 3.5 (2.0, 6.1) 0.97
Season at time of blood draw Spring 75 (30%) 89 (24%) 0.004
Summer 53 (22%) 129 (35%)
Fall 48 (20%) 73 (20%)
Winter 70 (28%) 82 (22%)
Northern latitude2 175 (71%) 178 (48%) <0.001
Vitamin D intake (IU/day) 138 (78, 267) 160 (95, 306) 0.10
Calcium intake (mg/day) 713 (476, 1,009) 710 (483, 1,027) 0.84
Percentage of body fat (%)3 25.3 (17.9, 33.2) 22.3 (15.1, 33.1) 0.06
Vitamin D (ng/mL) 15.5 (13.1, 17.7) 26.3 (23.2, 30.8) < 0.001
PTH (pg/mL) 33.7(23.8, 48.6) 27.2 (20.3, 38.1) < 0.001
PTH >65 pg/ml 25 (10%) 18 (5%) 0.01
Calcium (mg/dl) 9.5 (9.3, 9.8) 9.7 (9.4, 9.9) < 0.001
Phosphate (mg/dl) 4.6 (4.1, 5.1) 4.7 (4.3, 5.1) 0.02
Creatinine (mg/dL) 0.56 (0.49, 0.65) 0.54 (0.46, 0.64) 0.05
Among PHIV
Efavirenz – current use4 38 (23%) 33 (15%) 0.047
TDF use – current use4 34 (21%) 54 (25%) 0.35
CD4 T cell count (cells/mm3) 661 (462, 852) 728 (540, 974) 0.008
HIV RNA (log10 copies/mL) 2.60 (1.70, 3.28) 1.98 (1.70, 2.99) 0.11
Abbreviations: PHIV-perinatally HIV-infected; PHEU-perinatally HIV-exposed uninfected. PTH-parathyroid hormone; TDF-tenofovir; EFV-
efavirenz, 25(OH)D – 25 hydroxy-vitamin D.
1
Missing data for 25(OH)D ≤20 ng/mL and >20 ng/mL: Black race (N=7, N=20); dietary intake (N=8, N=26); percent body fat (N=14, N=15), 
PTH (N=0, N= 1); calcium (N=4, N=1), phosphate/creatinine (N=1, N=0); EFV/TDF (N=4, N=6); CD4 count (N=0, N=2).
2Northern latitude: ≥ 39° degrees latitude
3No percent body fat measure because there was no total body DXA scan performed within 365 days of 25(OH)D (N=14, N=15).
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4
Twelve PHIV children are not included in these numbers. For 8 children the last information on ARV use was just prior to the 25(OH)D date, for 2 
children ARV was started for the first time after the 25(OH)D date, and for 2 children ARVs were never used. Of the 8 children with previous ARV 
use just prior to the 25(OH)D date, 1 had been on TDF, 2 on EFV, 1 on TDF and EFV, and 4 on neither TDF or EFV.
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Table 4
Prevalence of Low 25(OH)D and High PTH and Differences in Levels by HIV status, and by Use of Efavirenz 
and Tenofovir
Prevalence of Low 25(OH)D
or High PTH
Difference in 25(OH)D
or PTH Levels
Prevalence Ratio (95%CI)
P value
Difference (95%CI)
P value
Exposure Unadjusted Adjusted1,2 Unadjusted Adjusted1
25(OH)D ≤ 20 ng/mL 25(OH)D (ng/mL)
Model 1A Model 1B2 Model 7A Model 7B
PHIV vs. PHEU 1.24 (0.99,1.54) 1.00 (0.81,1.24) −0.77 (−2.05,0.51) 0.48 (−0.69,1.65)
0.06 0.98 0.24 0.42
Model 2A Model 2B Model 8A Model 8B
PHIV EFV+ vs. PHEU3 1.52 (1.14,2.03) 1.30 (0.98,1.74) −2.83 (−4.93, −0.72) −1.94 (−3.88,0.01)
0.01 0.07 0.008 0.05
PHIV EFV− vs. PHEU3 1.17 (0.93,1.48) 0.95 (0.76,1.18) −0.31 (−1.64,1.01) 0.99 (−0.23,2.21)
0.17 0.63 0.643 0.11
Model 3A Model 3B Model 9A Model 9B
PHIV TDF+ vs. PHEU3 1.09 (0.79,1.51) 0.77 (0.56,1.06) −1.20 (−3.16,0.75) 1.02 (−0.87,2.92)
0.61 0.10 0.23 0.29
PHIV TDF− vs. PHEU3 1.28 (1.02,1.6) 1.06 (0.86,1.31) −0.65 (−1.99,0.70) 0.37 (−0.85,1.59)
0.03 0.58 0.35 0.55
PTH > 65 pg/mL PTH (pg/mL)
Model 4A Model 4B Model 10A Model 10B
PHIV vs. PHEU 3.80 (1.52,9.51) 3.17 (1.25,8.06) 7.10 (4.17,10.02) 5.26 (2.35,8.17)
0.004 0.01 <0.001 <0.001
Model 5A Model 5B Model 11A Model 11B
PHIV EFV+ vs. PHEU3 1.13 (0.22,5.69) 0.85 (0.17,4.56) 5.44 (0.61,10.28) 3.37 (−1.85,8.60)
0.88 0.89 0.03 0.21
PHIV EFV− vs. HEU3 4.40 (1.75,11.04) 3.67 (1.44,9.36) 7.27 (4.11,10.44) 5.54 (2.47,8.61)
0.002 0.006 <0.001 <0.001
Model 6A Model 6B Model 12A Model 12B
PHIV TDF+ vs. PHEU3 6.79 (2.54,18.12) 5.50 (1.95,15.49) 14.22 (9.11,19.32) 11.65 (6.47,16.83)
<0.001 0.001 <0.001 <0.001
PHIV TDF− vs. PHEU3 2.92 (1.13,7.6) 2.64 (1.01,6.94) 4.80 (1.69,7.91) 3.71 (0.61,6.82)
0.03 0.05 0.002 0.02
Abbreviations: PHIV-Perinatally HIV-infected; PHEU-perinatally HIV-exposed uninfected; TDF-tenofovir; EFV-efavirenz, 25(OH)D – 25 
hydroxy-vitamin D.
1
For the outcome 25(OH)D, the models were adjusted for age, black race, ancestry markers, latitude as a continuous variable, and season. For the 
outcome PTH, models were adjusted for age, black race, and ancestry markers.
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2
Model 1B, 2B, and 3B were fit using the Poisson link and the robust standard error.
3
In sensitivity analyses including children with ARV data just prior to the 25(OH)D date, and not on the 25(OH)D date, the results did not change 
for the TDF or EFV analyses.
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